These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 2697396)

  • 21. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
    Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
    Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes.
    Löffler H; Schmitz N; Gassmann W
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):619-31. PubMed ID: 1613010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Low-dose chemotherapy].
    Ogata K; Yamada T; Dan K
    Rinsho Ketsueki; 1996 Sep; 37(9):777-81. PubMed ID: 8914461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
    Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.
    Nagura E; Minami S; Nagata K; Morishita Y; Takeyama H; Sao H; Suzuki H; Naoe T; Yokomaku S; Mizuno H; Murase T; Hirabayashi N; Takeo T; Tanimoto M; Kawashima K; Saito H
    Nagoya J Med Sci; 1999 Nov; 62(3-4):135-44. PubMed ID: 10689875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reasons for treating secondary AML as de novo AML.
    Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
    Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Should patients over 65 years old with acute myeloid leukemia be treated with myelosuppressive chemotherapy?].
    Spataro V; Cometta A; Glauser MP; Schapira M; Grob JP
    Schweiz Med Wochenschr; 1995 Mar; 125(9):429-32. PubMed ID: 7892571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
    De Witte T; Zwaan F; Hermans J; Vernant J; Kolb H; Vossen J; Lönnqvist B; Beelen D; Ferrant A; Gmür J
    Br J Haematol; 1990 Feb; 74(2):151-5. PubMed ID: 2180469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C; Chi J; Wang L
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
    Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.
    Deschler B; de Witte T; Mertelsmann R; Lübbert M
    Haematologica; 2006 Nov; 91(11):1513-22. PubMed ID: 17082009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.